Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company ...
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused ...
WQRF Rockford on MSN
Skin infection alert issued for South Beloit High School students
South Beloit High School is notifying families after cases of a highly contagious skin infection were detected in several ...
Lakewood-Amedex Biotherapeutics Inc., a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, ...
Armata Pharmaceuticals ( ($ARMP) ) has issued an update. On October 22, 2025, Armata Pharmaceuticals announced positive results from its Phase 2a ...
A recent study found that every stuffed animal tested harboured bacteria like E. coli, posing risks to children's developing ...
Medpage Today on MSN
When Infection Forces Heart Device Removal, Shorter Antibiotic Course May Suffice
ATLANTA -- For patients with cardiovascular implantable electronic device (CIED)-associated infections, a shorter course of ...
SINGAPORE – The Republic is reviewing its action plan to better control the emergence and spread of future drug-resistant ...
Armata Pharmaceuticals (ARMP) stock soars 300% after the company announces promising Phase 2 trial results for its AP-SA02 antibacterial agent. Read more here.
Asianet Newsable on MSN
Armata Pharmaceuticals Stock Soars To Record High After Phage Therapy Data In Deadly Infection Trial; Retail Traders Pile In
The company’s bacteriophage therapy AP-SA02 achieved an 88% response rate in a Phase 2a trial for Staphylococcus aureus ...
An MIT team used artificial intelligence to design novel antibiotics, two of which showed promise against MRSA and gonorrhea.
Gym equipment harbors bacteria hundreds of times higher than household surfaces, with free weights and cardio machines being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback